Active immunization with pC protein of Borrelia burgdorferi protects gerbils against B. burgdorferi infection
- PMID: 1293055
- DOI: 10.1007/BF01710681
Active immunization with pC protein of Borrelia burgdorferi protects gerbils against B. burgdorferi infection
Abstract
Serious infection due to Borrelia burgdorferi and the disseminated infection characteristic of the disease possess unique treatment problems. The wide and still increasing incidence of Lyme borreliosis as well as the problems in treatment call for effective prevention strategies by active immunization. Vaccination experiments were done to determine if active immunization of gerbils with recombinant OspA and pC protects against infection with strains of B. burgdorferi. Gerbils were vaccinated with recombinant OspA and pC (20 kDa protein) and challenged four weeks later with a clone (derived from B. burgdorferi strain PKo) which expresses an abundant amount of pC but only little OspA. Non-immunized gerbils challenged with the same B. burgdorferi strain were used as controls. Both groups of immunized gerbils developed antibodies against the recombinant vaccines. The pC vaccinated group was protected against infection, whereas the OspA vaccinated group showed signs of infection. The non-vaccinated group developed generalised infection. These results show that pC should be considered as a further vaccine candidate and probably needs to be combined with OspA for an efficient vaccine against B. burgdorferi.
Similar articles
-
Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi.Infect Immun. 1995 Sep;63(9):3543-9. doi: 10.1128/iai.63.9.3543-3549.1995. Infect Immun. 1995. PMID: 7642289 Free PMC article.
-
An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi.J Infect Dis. 1997 Jan;175(1):91-7. doi: 10.1093/infdis/175.1.91. J Infect Dis. 1997. PMID: 8985201
-
Vaccination with meningococcal outer membrane vesicles carrying Borrelia OspA protects against experimental Lyme borreliosis.Vaccine. 2021 Apr 28;39(18):2561-2567. doi: 10.1016/j.vaccine.2021.03.059. Epub 2021 Apr 1. Vaccine. 2021. PMID: 33812741
-
Experimental immunization against Lyme borreliosis with recombinant Osp proteins: an overview.Infection. 1996 Mar-Apr;24(2):195-202. doi: 10.1007/BF01713339. Infection. 1996. PMID: 8740122 Review.
-
Prospects for a vaccine to prevent Lyme disease in humans.Clin Infect Dis. 1995 Nov;21(5):1267-74. doi: 10.1093/clinids/21.5.1267. Clin Infect Dis. 1995. PMID: 8589153 Review.
Cited by
-
DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.Infect Immun. 2001 Apr;69(4):2130-6. doi: 10.1128/IAI.69.4.2130-2136.2001. Infect Immun. 2001. PMID: 11254567 Free PMC article.
-
Genotypic and phenotypic characterization of Borrelia burgdorferi isolated from ticks and small animals in Illinois.J Clin Microbiol. 1995 Sep;33(9):2304-15. doi: 10.1128/jcm.33.9.2304-2315.1995. J Clin Microbiol. 1995. PMID: 7494019 Free PMC article.
-
Heterogeneity of BmpA (P39) among European isolates of Borrelia burgdorferi sensu lato and influence of interspecies variability on serodiagnosis.J Clin Microbiol. 1997 Nov;35(11):2752-8. doi: 10.1128/jcm.35.11.2752-2758.1997. J Clin Microbiol. 1997. PMID: 9350727 Free PMC article.
-
Sera from OspA-vaccinated dogs, but not those from tick-infected dogs, inhibit in vitro growth of Borrelia burgdorferi.J Clin Microbiol. 1995 Oct;33(10):2745-51. doi: 10.1128/jcm.33.10.2745-2751.1995. J Clin Microbiol. 1995. PMID: 8567917 Free PMC article.
-
Outer surface proteins E and F of Borrelia burgdorferi, the agent of Lyme disease.Infect Immun. 1994 Jan;62(1):290-8. doi: 10.1128/iai.62.1.290-298.1994. Infect Immun. 1994. PMID: 8262642 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous